When cells run low on energy, their survival depends on rapidly upshifting glucose metabolism — and how they orchestrate that response at the molecular level has been poorly understood. A newly described signaling cascade suggests that posttranslational modifications on glycolytic enzymes, not just transcriptional changes, are a primary driver of this adaptation, with implications for cancer metabolism, metabolic disease, and potentially longevity research.
Published in PNAS, the study identifies a metazoan-conserved regulatory axis involving the acetyltransferase KAT2 and the class IIa deacetylase HDACIIa working in concert to modulate the stability and activity of phosphoglycerate kinase (PGK) and aldolase (ALDO), two enzymes central to the glycolytic pathway. Under energy stress conditions, this KAT2/HDAcIIa–PGK–ALDO axis functions as a dual degradation inhibition cascade: by protecting both PGK and ALDO from proteasomal turnover, the cell effectively amplifies glycolytic flux without requiring new gene transcription. The conservation of this axis across metazoans points to an ancient, deeply embedded mechanism for metabolic resilience.
This finding sits at the intersection of epigenetic enzyme regulation and metabolic reprogramming — a field that has accelerated considerably since the recognition that acetylation rivals phosphorylation in its scope of metabolic control. What distinguishes this work is the dual-node protection mechanism: rather than a linear relay, KAT2 and HDAcIIa appear to coordinate simultaneously on two distinct glycolytic enzymes, creating a feedforward amplification loop. This architecture is notably efficient and could explain how tumors and hypoxic tissues sustain high glycolytic rates under nutrient limitation. For longevity biology, dysregulation of energy-sensing pathways like this one has been linked to accelerated cellular aging and senescence. Key limitations include the study's likely reliance on cell-line and model-organism data rather than human tissue validation, and the translational distance from mechanistic biochemistry to therapeutic application remains substantial. Still, as a mechanistic discovery, this qualifies as genuinely incremental-to-significant — it refines the molecular grammar of metabolic stress response in a way that could inform future drug targeting.